Mounjaro vs Rybelsus
A side-by-side look at two diabetes medications advertised on TV. Informational only — not medical advice.
| US Mounjaro | US Rybelsus | |
|---|---|---|
| Generic name | tirzepatide | semaglutide |
| Drug class | GIP/GLP-1 Receptor Agonist | GLP-1 Receptor Agonist |
| Treats | Type 2 diabetes | Type 2 diabetes |
| Category | Diabetes | Diabetes |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Year approved | 2022 | 2019 |
| FDA warning | Black box warning | Black box warning |
| Est. TV ad spend | $350M | $180M |
| Common side effects | Nausea, Diarrhea, Decreased appetite, Vomiting | Nausea, Abdominal pain, Diarrhea, Decreased appetite |
Frequently asked questions
Is Mounjaro or Rybelsus better?
Neither is universally "better." Mounjaro (tirzepatide) and Rybelsus (semaglutide) are both used for diabetes, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Mounjaro and Rybelsus?
Mounjaro is a GIP/GLP-1 Receptor Agonist made by Eli Lilly, while Rybelsus is a GLP-1 Receptor Agonist made by Novo Nordisk. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Mounjaro has the larger estimated TV advertising budget of the two.